ClinicalTrials.gg
Status unknownNCT02087540Updated Mar 14, 2014

Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia

A Phase 3 interventional study of Telmisartan 80mg and Rosuvastatin 20mg in Hypertension and Hyperlipidemia, sponsored by IlDong Pharmaceutical Co Ltd. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-03-14.

Sponsored by IlDong Pharmaceutical Co Ltd · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2014), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
310
Allocation
Randomized
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.

Planned enrollment
43rd of 99
310 · median 184
Started
2013
with 1 other
Phase 3
40 of 99
none open now
Registered
53rd of 99
by date
Lead sponsor
2 of 99
IlDong Pharmaceutical Co Ltd

Among the 99 studies testing telmisartan in Hypertension, this one is the 43rd largest by planned enrollment, is one of 2 that started in 2013, is one of 40 in phase 3, and was the 53rd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About telmisartan

Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies testing telmisartan in Hypertension, or all of them as a file.
02

Study summary

To identify efficacy and safety of Telmisartan/Rosuvastatin co-administration in hyperlipidemia control in hypertensive patients with hyperlipidemia compared to each monotherapy.

03

Conditions studied

  • Hypertension
  • Hyperlipidemia
04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Men and women >18 years of age
  • Subject who has one of 3 conditions classifed by Cardiovascular Risk Factors, 10-Year Risk, Blood Pressure, LDL-C, Coronary Artery Disease and Equivalent

Exclusion criteria

Exclusion Criteria:

  • Female who are pregnant, breastfeeding, or of , unwilling to practice adequate throughout the study,.
  • Other exclusions applied
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
310 participants (estimated)

Study arms

  • Experimental
    Telmisartan 80mg & Rosuvastatin 20mg

    PO, Once Daily, 8 weeks

    Drug: Telmisartan 80mg · Drug: Rosuvastatin 20mg · Drug: Placebo(for Rosuvastatin 10mg)

  • Experimental
    Telmisartan 80mg & Rosuvastatin 10mg

    PO, Once Daily, 8weeks

    Drug: Telmisartan 80mg · Drug: Rosuvastatin 10mg · Drug: Placebo(for Rosuvastatin 20mg)

  • Active comparator
    Telmisartan placebo & Rosuvastatin 20mg

    PO, Once Daily, 8 weeks

    Drug: Rosuvastatin 20mg · Drug: Placebo(for Telmisartan 80mg) · Drug: Placebo(for Rosuvastatin 10mg)

  • Active comparator
    Telmisartan Placebo & Rosuvastatin 10mg

    PO, Once Daily, 8 weeks

    Drug: Rosuvastatin 10mg · Drug: Placebo(for Telmisartan 80mg) · Drug: Placebo(for Rosuvastatin 20mg)

  • Active comparator
    Telmisartan 80mg & Rosuvastatin placebo

    PO, Once Daily, 8 weeks

    Drug: Telmisartan 80mg · Drug: Placebo(for Telmisartan 80mg) · Drug: Placebo(for Rosuvastatin 20mg)

  • Placebo comparator
    Telmisartan placebo & Rosuvastatin placebo

    PO, Once Daily, 8 weeks

    Drug: Placebo(for Telmisartan 80mg) · Drug: Placebo(for Rosuvastatin 20mg) · Drug: Placebo(for Rosuvastatin 10mg)

Interventions

06

What researchers measure

Primary outcomes

  1. •Change in seated diastolicblood pressure at 8 weeks compared to the base value

    Time frame: at the 8 weeks

  2. Change in LDL-Cat 8 weeks compared to the base value (% change)

    Time frame: at the 8 weeks

Secondary outcomes

  1. Change in seateddiastolic blood pressure

    Time frame: at 2,4 8 weeks

  2. Change in seated systolic blood pressure

    Time frame: at 2,4,8weeks

  3. Rate of patients achieving a therapeutic purpose according to JNC VII Guideline [therapeutic purpose for blood pressure: < 140/90 mmHg (however, < 130/80 mmHg for Group III)]

    Time frame: at 2, 4 and 8 weeks

  4. Change in LDL-Cat compared to the base value (% change)

    Time frame: 2, 4 and 8 weeks

  5. Change in TC, TG, HDL-C and Apolipoprotein B compared to the base value (% change)

    Time frame: at 2, 4 and 8 weeks

  6. Rate of patients achieving a therapeutic purpose according to NCEP ATP III Guideline therapeutic purpose for LDL-C- (Group I: < 160 mg/dL, Group II: < 130 mg/dL, Group III: < 100 mg/dL)

    Time frame: at 2, 4 and 8 weeks

07

Study locations

1 of 1 sites recruiting
  • The Catholic University of Saint Mary's Hosiptal
    Seoul, Korea, Republic of
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2013 and a primary completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2014
First posted
Mar 14, 2014
Start
May 2013
Primary completionEst.
Dec 2014
Last update
Mar 14, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02087540
Responsible party
Sponsor
First posted
Mar 14, 2014
Start date
May 2013
Primary completion
Dec 2014 (estimated)
Last update
Mar 14, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telmisartan · Rosuvastatin

Start the discussion